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Screening for Early Asymptomatic Pheochromocytoma in MEN-2
Margareta Telenius-Berg,* Bertel Berg, Bertil Hamberger, and Sten Tibblin

Pheochromocytoma is a major cause of morbidity in multiple endocrine neoplasia type 2. We
recommend a similar diagnostic screening approach for early asymptomatic pheochromocytoma as is
generally acceptedfor asymptomatic medullary thyroid carcinoma. We present a new provocative test
for early asymptomatic pheochromocytoma. Plasma epinephrine levels and epinephrine/dopamine
ratios after physical exercise seem to have higher sensitivity than basal plasma catecholamine levels.
Specificity is high especially for discrimination from neurovegetative lability, which is the clinically
most important differential diagnosis. (Henry Ford Hosp Med J 1987;35:110-4)

P

heochromocytomas in multiple endocrine neoplasia type 2
(MEN-2) have a serious prognosis with high mortality if not
treated early. Ten percent of MEN-2 patients who sought medical advice for symptoms of medullary thyroid carcinoma (MTC)
and/or pheochromocytoma died from the latter tumor, and another 24% died from MTC, according to retrospective analysis
(1). One of three patients with symptomatic pheochromocytoma
died from this tumor. The mean age at death in our 46 Swedish
MEN-2 patients with pheochromocytoma was 41 years (1). Mortality from MTC has been markedly reduced by screening, early
diagnosis, and treatment. An important future goal of family
screening is early diagnosis and treatment of the adrenal tumors
in MEN-2.

Problems in Diagnosing Pheochromocytoma
Clinical symptoms are varied and most unreliable as indicators ofthe diagnosis. The majority of our patients did not have
the classical paroxysmal symptoms combined with hypertensive crises. Many of our patients even denied symptoms before
surgery: they had become used to fatigue, spells of tachycardia,
and sweating. Clinical diagnosis has a low sensitivity and many
false-negative and false-positive diagnoses are common. The
most important differential diagnosis—by far outnumbering
pheochromocytoma—is neurovegetative lability or "hyperdynamic beta-adrenergic state" (2). These patients have
clinically and biochemically a "phenotypic pheochromocytoma
syndrome."
Is screening for asymptomatic pheochromocytoma
indicated?
This concern seems to parallel discussions of MTC in the
1970s: What is the proper approach to patients with high semm
calcitonin but no identifiable tumor—"wait-and-see" or surgery? After a prospective follow-up we were able to show that
both morbidity and mortality decreased after active screening

no
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for MTC (I). Pheochromocytoma is a potentially life-threatening tumor in which the first symptoms may be missed and cardiovascular hypertensive crises may come without waming. In
our opinion screening for early pheochromocytoma presents
several advantages:
1) Early diagnosis and operation will decrease the risk of
cardiovascular crises in association with childbirth, surgery, or
unexpected accidents.
2) Early detection of adrenal disease allows the possibility to
choose subtotal adrenalectomy with preservation of the adrenal
cortex (3), Furthermore, we have advocated the use of unilateral
adrenalectomy in cases where tumor development is highly
asynchronous and where one adrenal seems free from tumor (4).
3) Diagnostic screening is also important as a means of increasing our knowledge of the natural history of this component
of the MEN-2 syndrome.
With few exceptions (5) most previous diagnostic experience
has been gained from studies of sporadic pheochromocytomas
and those conclusions may not be transferable to the pheochromocytomas in MEN-2.
Diagnostic techniques
Even in symptomatic pheochromocytoma the diagnosis
cannot be made purely on clinical grounds. Biochemical and
morphological techniques for localization of the tumor(s) are
needed but no single method combines both high sensitivity and
high specificity. Combinations of diagnostic methods are
required but little experience or data are available for the
asymptomatic patient with adrenal medullary hyperplasia or
early tumors.
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Biochemical techniques
Tests for the hormones produced by the adrenal tumor(s) are
the starting point. For MTC diagnosis, the calcitonin (CT) peptide has the advantage of being fairly stable. In contrast, plasma
catecholamine specimens need rapid and meticulous handling
by experienced staff. Plasma levels fall within minutes after an
in vivo surge. In vitro their instability is the most severely limiting factor for obtaining reliable results. Many different methods
for catecholamine assay are available, but only a few have
been properly validated and large discrepancies may occur
between laboratories (6).
Another problem is the normalfluctuationof plasma levels
after even minor stress, which can cause false-positive results.
Even in pheochromocytoma, catecholamine release is intermittent, and basal plasma levels are not consistently raised (7,8).
Consequently, urine analysis of catecholamines and their metabolites remains the cornerstone of screening programs in most
centers. Diagnostic efficiency has been improved by the introduction of new analytical methods, Gagel et al (5) have emphasized that an increased epinephrine/norepinephrine ratio
in urine is typical for early hereditary pheochromocytoma. Unfortunately, poor patient compliance in collecting 24-hour urine
samples is common and interaction with antihypertensive
drugs is an increasingly common problem.
Provocative (stimulation/inhibition) tests
Older pharmacological testing with histamine and phentolamine has almost been abandoned because of low diagnostic
accuracy and the risks of serious complications. In our experience, even the glucagon stimulation test does not have the desired sensitivity and specificity. The clonidine suppression test
introduced by Bravo et al (9) seems to be able to discriminate
pheochromocytoma from other causes of catecholamine excess.
This centrally acting alpha-adrenergic antagonist suppresses
neurogenically-mediated release of catecholamines but not
the autonomous secretion from adrenal medullary tumors.
Sensitivity and specificity are high in sporadic symptomatic
tumors with high norepinephrine secretion. Since the pheochromocytomas in MEN-2 appear to have a different secretory
pattem (predominantly epinephrine), only empirical trials can
evaluate the sensitivity of this procedure in MEN-2.
Exercise test
No pharmacological test for diagnosing pheochromocytoma
has gained general acceptance. Since any manipulation of
patients with adrenal tumors (whether it be pharmacological
or with a more physiological test such as exercise) involves risk
taking, the aim should be to find as safe a test as is consistent
with good diagnostic efficiency.
Physical exercise may provoke release of plasma catecholamines both in healthy subjects and in pheochromocytoma
patients. This was the basis of the exercise test which we
recently proposed (10). This procedure might also provide information on the risks of physical exercise in everyday life for
patients without clinical symptoms.
Our aim was to find a practical, simple, noninvasive
provocative test which would satisfy the requirements listed in
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Table 1
Pheochromocytoma in MEN-2: Requirements of
an Ideal Screening Test
Simple to perfomi by the patient
Simple to supervise by nonspecialized medical staff
Suitable for outpatient screening
Repeatable
No premedication
No special equipment
No special drugs or radiopharmaceuticals
No ionizing radiation
High sensitivity
High specificity

Table 1 and would also be suitable for individuals of varying
ages and degrees of physical fitness.
In healthy subjects elevation of plasma epinephrine occurs
predominantly when the patient approaches exhaustion and then
at the onset of anaerobic metabolism (11). To minimizeriskswe
should stop short of that stage. In standardizing the work load
the patients were allowed to work until "really tired" but not yet
"exhausted," ie, to a level of submaximal exercise.

Patients and Methods
Twenty-six MEN-2 gene carriers were examined. Eight of
these had asymptomatic pheochromocytoma(s) (the smallest
tumor verified by operation was 9 mm in diameter). Nine had
undergone surgery for MTC but had no clinical or biochemical
evidence of pheochromocytoma. Four patients had had unilateral adrenalectomy and six patients had had bilateral adrenalectomy without evidence of new or residual pheochromocytoma.
Seventeen clinically healthy individuals (age- and sexmatched to the 17 patients in the pheochromocytoma and
MTC groups) served as controls, as did 11 patients with
neurovegetative lability who had symptoms mimicking
pheochromocytoma. In this latter group, pheochromocytoma
had been mied out by current diagnostic tests (in some patients
including computed tomography) over at least a two-year
follow-up.
The stress test was performed on an electrically-braked
bicycle ergometer. The work load was increased continuously
until the patient felt uncomfortable fatigue but not extreme exhaustion. Heart rate, blood pressure, and ECG were recorded.
Blood samples for basal (pre-exercise) plasma catecholamine
analysis were drawn from an indwelling venous catheter after
the patient had rested for 30 minutes in a supine position,
Postexercise catecholamine samples were drawn immediately
after exercise with the patient lying down beside the bicycle.
The patients were nonfasting to avoid a hypoglycemic rise in
catecholamines. Plasma catecholamines were analyzed by high
performance liquid chromatography using electrochemical
detection (12).

Results
The wide variation in the increments of all three plasma catecholamines after exercise probably reflects the degree of exhaustion during the test. For norepinephrine and dopamine both
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Fig 1—Plasma catecholamines before and after exercise in patients with pheochromocytoma (a; n = 8), neurovegetative lability
(b; n = 11), and healthy controls (c; n = 17). Lines denote median and range levels expressed as percent of median for healthy
controls. NE = norepinephrine, E = epinephrine, and E/DA = epinephrine/dopamine ratio.

basal and postexercise levels were about the same for all three
groups (Fig 1). Subjects with neurovegetative lability tended to
have higher dopamine levels after work.
Healthy controls and bilaterally adrenalectomized patients
did not differ significantly in norepinephrine and dopamine
increments, blood pressure, or heart rate during work. We
conclude that at least the main contribution of norepinephrine
and dopamine is extra-adrenal sources. Norepinephrine
and dopamine levels after exercise probably reflect sympathetic
nerve activity.
Epinephrine differed from the other plasma catecholamines.
Basal levels were higher than for the controls in two groups: five
out of eight pheochromocytoma patients and four out of 11
neurovegetative lability patients. The highest level for the
healthy controls (0.15 nmol/L) was chosen as the cutoff point.
Thus, a clear overlap was seen between the two groups of
clinical importance, pheochromocytoma and pheochromocytoma-like neurovegetative lability (Fig 1).
Postexercise plasma epinephrine levels increased markedly in
all groups except in the bilaterally adrenalectomized patients in
whom there were no increments at all. This indicates that practically all epinephrine, especially that released during exercise,
originates in the adrenal glands (Fig 1).
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During work the pheochromocytoma patients increased their
epinephrine levels most, significantly higher than for both
healthy controls and neurovegetative lability patients (p <
0.001). Six out of eight pheochromocytoma patients had levels
higher than the cutoff point (2 nmol/L), as had one of nine
MTC patients, two of 17 healthy controls, but none of the 11
neurovegetative lability patients.
Postexercise epinephrine/dopamine ratio
After work epinephrine/dopamine ratios also were significantly higher in the pheochromocytoma patients than in healthy
controls (p < 0,001) or patients with neurovegetative lability
(p < 0.001). With an arbitrary cutoff point at six, a high ratio
was seen in seven out of seven assessable patients with pheochromocytoma (an eighth patient could not be evaluated because
of L-DOPA treatment). High ratios were also seen in three of 17
healthy controls and five out of nine MTC patients, but not in
any of the patients with neurovegetative lability nor those who
had had unilateral or bilateral adrenalectomy (Table 2).
The results can also be plotted as in Fig 2. The clear separation between the pheochromocytoma and neurovegetative
lability groups was even greater if the relatively high dopamine
level for the latter group was taken into account (Fig 2).
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Table 2
Plasma Catecholamine Levels Before and After Exercise

Epinephrine
(nmol/L):
Before: mean
median
range
After: mean
median
range
Epinephrine/
dopamine ratio:
Before: mean
median
range
After: mean
median
range

Pheochromocytoma

Neu ro vegetative
Lability

Healthy
Controls

0,3
0,24
0,05 to 0,8
3,6
2,8
1,3 to 9,5

0,14
0,09
0,05 to 0,34
0,49
0,28
0,07 to 1,53

0,07
0,06
0,03 to 0,12
1,22
0,86
0,05 to 6,4

2.7
3,9
0,20 to 4,5
21,7
14,8
6,7 to 50

1,50
1,14
0,23 to 4,5
1,45
1,13
0,24 to 3,7

1,39
1.25
0,08 to 5,0
4,06
3,1
0,26 to 12

Although our pheochromocytoma patients were asymptomatic, five out of eight had raised basal plasma epinephrine
levels, ie, sensitivity was 0.6. Specificity was suboptimal (0,6)
in respect to the group with neurovegetative lability: several
false-positive results were seen. This illustrates that il is not sufficient to have a good discrimination versus healthy controls but
that one should include a control group of patients presenting
clinical difficulties in diagnostic work.
The postexercise epinephrine/dopamine ratio completely separated patients with pheochromocytoma from those with neurovegetative lability. The syndrome of neurovegetative lability
seems to be associated with increased basal levels of plasma
catecholamines but the response to exercise is subnormal.
The cardiovascular response did not differ between pheochromocytoma patients and the other groups. It therefore seems
probable that moderate exercise in asymptomatic patients with
MEN-2 pheochromocytoma does not carry a great risk for severe cardiovascular reactions.
Imaging techniques
Clinical chemistry techniques are primarily used to diagnose
the presence of a catecholamine-producing tumor. The next step
is to verify the diagnosis and localize the tumor. Imaging techniques should rarely be used as first line examinations of the
patient with suspected pheochromocytoma. Despite their advantages, these methods were not intended nor are they suitable
for repeated regular screening of MEN-2 families. Arterial angiography has been replaced by newer techniques. Venous
catheterization for sampling plasma catecholamines is seldom
needed in MEN-2 pheochromocytoma, as this is primarily a tumor of the adrenal medulla. Computed tomography has been a
great diagnostic advance. Sensitivity is high if the tumor is
larger than 10 mm in diameter. However, even with much experience, interpretation is often difficult in small tumors.
Meta-iodo-benzylguanidine (MIBG) scintigraphy and computed tomography are complementary (13). MIBG is taken up in
neuroectodermal tissues and thus provides both morphological
and metabolic evidence of a chromaffin tumor. In our experience
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Fig 2—Relationship between median results for postexercise
epinephrine and dopamine in the six diagnostic groups. PHEO
= pheochromocytoma, MTC = medullary thyroid carcinoma,
UA = unilaterally adrenalectomized, BA = bilaterally
adrenalectomized, HC = healthy controls, and NVL =
neurovegetative lability.
with pheochromocytomas in MEN-2, MIBG provides good
results with tumors 15 mm or more in diameter. The practical
problems in MIBG use involve availability, cost, and the need to
stay several days in the hospital. The radiation dose is high both
for computed tomography and for MIBG and therefore they cannot be used for repeated screening in young, fertile individuals.

Acceptability of screening for pheochromocytomas
Most members of MEN-2 families are aware of the morbidity
and mortality of the syndrome and of the rationale for screening
measures aimed at early diagnosis and therapy. Compliance
with screening is therefore very good. To achieve full acceptability the screening test must meet the criteria listed in Table 1.
MEN-2 families are a high-risk population. This is a major
factor in raising the predictive value of a positive test. With rare
exceptions, the MTC tumor will be the first tumor to develop
and it can be detected and diagnosed early in life. Therefore,
MTC may be considered a specific marker for probable future
development of the adrenal tumors, and screening for pheochromocytoma may be restricted to the documented carriers of
the MEN-2 gene.
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Conclusion
We believe that screening for asymptomatic pheochromocytoma in MEN-2 is indicated, just as for MTC. This will
have advantages both for the individual patient as well as for our
understanding and management of the syndrome as a whole.
The new stress test using physical exercise seems to bave better
diagnostic efficiency than measurement of basal plasma catecholamine levels only. The epinephrine/dopamine ratio seems
valuable, especially for the clinically important differential
diagnosis of neurovegetative lability.
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